HealthTech & AI

Discover how artificial intelligence and healthtech are transforming healthcare and drug development.

Nicole Dale

Anthropic’s Gates Foundation Partnership and Healthcare AI

Pharmatica image of a glass globe illuminated from within by bright yellow light, surrounded by blue data lines, symbolising AI bringing light, intelligence, and innovation to global healthcare through the Anthropic and Gates Foundation Partnership.

See how Anthropic's Gates Foundation partnership and Long-Term Benefit Trust could lead the way in shaping responsible AI governance across healthcare innovation.

Nicole Dale

Can Large Language Models Solve More Rare Disease Genomes?

Pharmatica image showing a clinical geneticist using LLM-assisted rare disease diagnosis tools to analyse genome sequencing data and generate evidence-based diagnostic hypotheses for precision medicine.

LLM-assisted rare disease re-assessment improved genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.

Nicole Dale

Can Large Language Models Solve More Rare Disease Genomes?

LLM-assisted rare disease re-assessment improved genomic analysis, increasing diagnostic yield and supporting clinician-led precision medicine and possibly drug development.

Nicole Dale

Foundational AI In Cell and Gene Therapy Development Success

Pharmatica image representing AI in cell and gene therapy development success through improving drug discovery, viral vector engineering, manufacturing, and predictive quality control.

Discover why AI in cell and gene therapy is necessary for successful development by improving drug discovery, viral vector engineering, manufacturing, and quality control.

Nicole Dale

Eli Lilly and AtaiBeckley: AI and Psychedelic Biotech Converge

Pharmatica image showing an anatomically accurate human brain with subtle neural activation inspired by functional MRI imaging, representing psychedelic biotech, mental health therapeutics, CNS drug discovery, and AI-enabled pharmaceutical innovation.

Eli Lilly's acquisition of Peter Thiel’s backed AtaiBeckley highlights growing investment in psychedelic biotech and the future of CNS drug discovery.

Nicole Dale

Claude Science: An Operating System for AI-Driven Pharma R&D

Pharmatica photo‑realistic representation of scientists collaborating in a unified AI‑driven pharmaceutical research environment using Claude Science, integrating genomics, structural biology, cheminformatics, and AI-assisted pharmaceutical research

Claude Science is a new AI R&D tool for drug discovery, integrating 60-plus scientific databases into one place. Here is what pharma R&D teams need to know.

Nicole Dale

Europe’s Life Sciences Strategy. A New Era of Innovation?

Pharmatica picture of European pharmaceutical innovation showing biotechnology research, advanced manufacturing, artificial intelligence, and regulatory collaboration supporting the European Life Sciences Strategy.

The new European Life Sciences Strategy aims to accelerate pharmaceutical innovation through investment, regulatory reform, biotechnology, and AI capabilities.

Nicole Dale

AI and Neuroscience. Why Big Pharma Is Betting on the Brain

Pharmatica’s AI in neuroscience graphical concept showing a digital brain connected to pharmaceutical research, precision psychiatry, biomarkers, and advanced artificial intelligence technologies.

AI in neuroscience is driving big pharma investment. Discover how AI neuroscience platforms are driving precision psychiatry and psychedelic therapeutics.

Nicole Dale

Anthropic’s Big AI Drug Discovery Announcement

Anthropic drug discovery programme combines AI research with pharmaceutical R&D as a scientist uses advanced analytics to accelerate neglected disease drug discovery.

Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.

Shubhangi Dua

How AI Is Reshaping Data Integrity in Pharma Manufacturing

In the recent episode of The Chain Reaction podcast, Nour AlSaleh, Founder and CEO of Veragence Pharma Consultancy, sat down with host Shubhangi Dua, Podcast Producer and B2B Journalist at Pharmatica.io and EM360Tech. AlSaleh shares her expertise on maintaining data integrity in this new era of AI and changing policies.

Veragence CEO Nour AlSaleh discusses how AI is transforming data integrity in pharma manufacturing, regulatory compliance, the "human-in-the-loop" requirement, and patient safety in the era of AI-driven GxP systems.

Nicole Dale

Digital Measures in Clinical Trials: FDA vs EMA Pathways

Clinician reviewing digital measures in clinical trials on a tablet, illustrating regulatory acceptance of digital health technologies, digital biomarkers, and FDA and EMA qualification pathways for modern clinical research.

Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.

Nicole Dale

FDA Draft Guidance on Gene Editing Safety (2026)

DNA double helix illustrating the FDA gene editing draft guidance 2026, highlighting next-generation sequencing (NGS) safety assessment, off-target editing analysis, genomic integrity testing, and regulatory requirements for cell and gene therapy development.

The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.

Content type